Abstract
The objective of our study was to determine the prevalence of neuropsychiatric manifestations and anti-ribosomal P antibodies (aRP) in SLE and to examine the diagnostic utility and associations of aRP with neuropsychiatric and other disease manifestations. Thirty two consecutive SLE patients, diagnosed according to the updated 1997 ACR criteria, were studied. A full medical history, rheumatological, neurological, psychiatric examination, and psychometric evaluation, including a battery of tests for cognitive dysfunction and the Symptom Checklist-90-Revised depression and anxiety scales were administered to all patients. Disease activity was scored using the SLEDAI. Neuropsychiatric manifestations were diagnosed and categorized according to the 1999 ACR case definitions for 19 NPSLE syndromes. Laboratory and serologic tests including ANA, anti-ds DNA, anti-cardiolipin antibodies (aCL) and aRP (ELISA) were also carried out. Twenty six (81.2%) patients had one or more NP manifestations. Depression (59.4%), headache (46.9%) and cognitive dysfunction (37.5%) were the commonest NPSLE syndromes. Other less commonly detected manifestations included seizures, anxiety, acute confusional state, stroke, and psychosis. aRP was positive in seven (21.9%) patients, all of whom had one or more NPSLE syndromes. Patients with psychiatric manifestations in general and mood disorders in particular had significantly higher mean titers of aRP than patients without these disorders (p < 0.05). aRP were found to be significantly associated with a younger age at the onset of SLE, with more severe articular manifestations and with the presence but not the severity of depression. aRP were highly specific for NPSLE and depression, and they were highly sensitive for psychosis. Neuropsychiatric manifestations are found in 81.2% of unselected Egyptian SLE patients. The presence of aRP antibodies positively predicts patients with psychiatric manifestations in general and mood disorders in particular, for which aRP is specific, but not sensitive. However, aRP is sensitive for psychosis, so that its absence in patients with SLE may help exclude Lupus psychosis.
Similar content being viewed by others
References
Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308
Nadeau SE (2002) Neurologic manifestations of connective tissue disease. Neurol Clin 20:151–178
Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:308–318
Jacobsen S, Petersen J, Ullman S et al (1998) A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol 17:478–484
Hanly JG, McCurdy G, Fougere L et al (2004) Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 31:2156–2162
Ainiala H, Loukkola J, Peltola J et al (2001) The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57:496–500
Brey RL, Holliday SL, Saklad AR et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58:1214–1220
ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608
Hanly JG, Hong C, Smith S et al (1999) A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 42:728–734
Hochberg MC (1997) Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
Elkon KB, Parnassa AP, Foster CL (1985) Lupus autoantibodies target ribosomal P proteins. J Exp Med 162:459–471
Schneebaum AB, Singleton JD, West SG et al (1991) Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythamatosus. Am J Med 90:54–62
Nojima Y, Minota S, Yamada A et al (1992) Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 51:1053–1055
Press J, Palayew K, Laxer RM et al (1996) Anti-ribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 99:671–676
Sato T, Uchiumi T, Ozawa T et al (1991) Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol 18:1681–1684
van Dam A, Nossent H, de Jong J et al (1991) Diagnostic value of antibodies against ribosomal phosphoproteins: a cross sectional and longitudinal study. J Rheumatol 18:1026–1034
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington (DC)
El-Behairy AA (1984) The Symptom Checklist-90-R. Cairo, El-Nahda El-Misrya
Wechsler D (1981) Wechsler adult intelligence scale-revised manual. Psychological, New York
Wechsler D (1971) Wechsler memory scale. Psychological, New York
Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI.A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640
Uribe AG, Vilá LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcón GS (2004) The systemic Lupus activity measure-revised, the Mexican systemic Lupus erythematosus disease activity index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 31:1934–1940
Tzioufas AG, Tzortzakis NG, Panou-Pomonis E et al (2000) The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis 59:99–104
Karassa FB, Loannidis JP, Toulomi G et al (2000) Risk factor for CNS involvement in systemic lupus erythematosus. QJM 93:169–174
Mok CC, Lau CS, Wong RWS et al (2001) Neuropsychatric manifestations and their clinical association in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 28:766–771
Isshi K, Hirohata S (1996) Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 39:1483–1490
Teh L-S, Lee MK, Wang F et al (1993) Anti-ribosomal P protein antibodies in different populations of patients with systemic lupus erythematosus. Br J Rheum 32:663–665
Abdel-Nasser AM, Abd El-Azim S, Taal E et al (1998) Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br J Rheumatol 37:391–397
Arnett FC, Reveille JD, Moustopoulos HM et al (1996) Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum 39:1833–1839
Sfikakis PP, Mitsikostas DD, Manoussakis MN et al (1998) Headache in systemic lupus erythematosus. Br J Rheumatol 37:300–303
Appenzeller S, Costallat LT (2004) Clinical implications of migraine in systemic lupus erythematosus: relation to cumulative organ damage. Cephalalgia 24:1013–1015
Weiner S, Otte A, Schumacher M et al (2000) Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 59:377–385
Harrison MJ (2002) Cognitive dysfunction in neuropsychiatric systemic lupus erythematosus. Curr Opin Rheumatol 14:510–514
Sanna G, Bertolaccini ML, Cuadrado MJ et al (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985–992
Teh L-S, Isenberg DA (1994) Anti-ribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum 37:307–315
Teh L-S, Bedwell AE, Isenberg DA et al (1992) Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis 51:489–494
Reichlin M, Broyles TF, Hubscher O et al (1999) Prevalence of autoantibodies to ribosomal P proteins in juvenile onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 42:69–75
Ghirardello A, Doria A, Zampieri S et al (2000) Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum 59:975–981
Karassa FB, Afeltra A, Ambrozic A et al (2006) Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 54:312–324
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors have no conflicts of interest or disclosures.
Rights and permissions
About this article
Cite this article
Abdel-Nasser, A.M., Ghaleb, R.M., Mahmoud, J.A. et al. Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. Clin Rheumatol 27, 1377–1385 (2008). https://doi.org/10.1007/s10067-008-0921-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-008-0921-1